1. Report Industry Investment Rating - Not provided in the given content 2. Core Viewpoints of the Report - In 2025Q3, the performance of major asset classes showed a "strong stocks, weak bonds" characteristic. Equity and convertible bond funds led the market, while pure bond funds and first - and second - tier bond funds underperformed. The scale of "fixed income +" funds rebounded, and the convertible bond strategy was advantageous. Convertible bond - enhanced funds performed brightly, but with relatively high volatility [11][23][42]. 3. Summary According to the Table of Contents 3.1 2025Q3, How Did "Fixed Income +" Funds Perform? 3.1.1 Stock - Strong, Bond - Weak, Equity Funds Led the Market - In 2025Q3, major asset classes showed a "strong stocks, weak bonds" characteristic. The equity market rose from July to August and entered a shock - adjustment period in September, while the bond market oscillated and corrected. The Wande All A, ChiNext Index, and Science and Technology Composite Index rose by 19.46%, 50.40%, and 39.61% respectively. The CSI Convertible Bond Index rose by about 9.43%. Equity and convertible bond funds led the market, with median returns of stock - type and partial - stock hybrid funds generally over 20% and that of convertible bond funds reaching 13%. Pure bond funds and first - and second - tier bond funds underperformed. Passive index - type stock funds and second - tier bond funds saw an increase in net asset value and shares, while pure bond funds were redeemed [11]. 3.1.2 "Fixed Income +" Scale Rebounded, Convertible Bond Strategy was Advantageous - After re - defining "fixed income +" funds based on post - event asset allocation, 1424 funds were selected for analysis. As of 2025Q3, the total share of these funds was 151.5461 billion, a 32.22% increase from the end of Q2, and the total net asset value was 2.0363 trillion yuan, a 36.5% increase. The convertible bond positions of "fixed income +" funds generally decreased at the end of Q3. Over 93% of "fixed income +" funds had positive returns in 2025Q3, and convertible bond - enhanced funds performed brightly but with relatively high volatility [23][24][31]. 3.2 Which High - Performing "Fixed Income +" Funds Led the Market? 3.2.1 Performance Review of Existing "Fixed Income +" Funds - Among the top 30 "fixed income +" funds with the highest returns in 2025Q3, convertible bond - enhanced funds dominated. Southern Changyuan Convertible Bond, Huashang Shuangyi, etc. had nearly 29% positive returns, and Huashang Shuangyi had a maximum drawdown within 4%. In the top 30 stock - enhanced funds, Huaxia Fund had multiple products on the list. The top 30 ordinary "fixed income +" funds were more scattered [47][52]. 3.2.2 Performance Review of Newly - Issued "Fixed Income +" Funds - Among the potential "fixed income +" funds newly established since 2024, Shangzheng Zhengtai Balanced Allocation and Quanguo Research Selection had over 11% positive returns in 2025Q3 and a maximum drawdown of about 2%. The remaining top 30 were mostly second - tier bond funds, with over 80% bond positions and about 10% equity positions, and their Q2 returns were mostly within 5% and the maximum drawdowns were mostly within 2% [56]. 3.3 What Were the Characteristics of the Holdings of High - Performing "Fixed Income +" Funds? 3.3.1 History: Which Directions Did High - Performing Funds Invest in? - At the end of 2025Q2, top "fixed income +" funds and convertible bond - enhanced funds significantly over - allocated manufacturing - chain convertible bonds and under - allocated financial convertible bonds. They also over - allocated partial - stock and high - price convertible bonds and under - allocated high - rated convertible bonds. In terms of stock industry allocation, they over - allocated metals, steel, power equipment, electronics, and computers [4]. 3.3.2 Present: Which Directions Are High - Performing Funds Investing in? - High - performing "fixed income +" funds continued to significantly over - allocate convertible bonds in metals, mid - stream manufacturing, and TMT sectors and under - allocate bank convertible bonds. They over - allocated high - price convertible bonds above 130 yuan and partial - stock convertible bonds and under - allocated medium - price convertible bonds between 110 - 130 yuan. They also over - allocated stocks in metals and electronics and under - allocated cyclical and financial stocks. Seventeen convertible bonds such as Haoyuan Convertible Bond were held by over 15 top "fixed income +" funds, and 17 convertible bonds such as Yunji Convertible Bond and Daotong Convertible Bond were held by over 20% of top "fixed income +" funds [4].

固定收益 | 固定收益定期 3M 买断式何以"等量"？ 证券研究报告 流动性跟踪 1、核心观点 月初，资金季节性平稳占主导，扰动主要在于国债的集中发行和逆回购回 笼规模较高，受此影响，临近周末，资金面出现小幅收敛，有三点关注： （1）逆回购投放相对克制，资金小幅收敛。单日净回笼规模均超 2000 亿 元，月初净回笼规模为二季度以来偏高水平，或受此影响，叠加周五两只 国债集中发行，资金泛起"小涟漪"；（2）10 月央行恢复购债，其意义不 仅在于作为一项流动性投放的工具，或也是引导曲线形态的抓手。尽管当 前资金宽松对短端的进一步催化相对有限，但长端或因此获得潜在"支撑"， 博弈空间有所打开。（3）跨月后，存单利率窄幅震荡，或因月初到期规模 不高，续发压力有限。同时，MLF、买断式逆回购投放在量和价上或均有 一定利好，叠加 10 月末短端利率的下行，或也凸显存单性价比。 值得关注的是，自 6 月买断式逆回购操作改革以来，3M 买断式多在月初 落地，且多为超额续作，仅 9 月和 11 月例外，或反映了银行为负债端管理 保留灵活性的考量。9 月、11 月的共性在于，月初资金平稳、扰动因素有 限，银行通过买断式逆回购补充 ...

Investment Rating - The investment rating for the company is "Accumulate" with a downward adjustment [4][7]. Core Views - The company's brand operation business remains stable, but increased expenses have put pressure on profits [1][3]. - The core brand operation business achieved revenue of 4.101 billion yuan, remaining flat year-on-year, while the wholesale distribution business saw a significant decline of 28.85% [2]. - The company has adjusted its revenue and profit forecasts for 2025-2026 due to the ongoing compression of the wholesale business and increased marketing expenses [4]. Financial Performance Summary - For the first three quarters of 2025, the company reported revenue of 5.627 billion yuan, a decrease of 8.41% year-on-year, and a net profit attributable to the parent company of 476 million yuan, down 25.67% [1]. - In Q3 2025, the company achieved revenue of 1.876 billion yuan, a decline of 12.85% year-on-year, but net profit increased by 31.43% to 313 million yuan [1]. - The company’s core brand operation revenue was 4.101 billion yuan, showing a year-on-year growth of 11.08% after adjusting for the two-invoice system [2]. Expense and Profitability Analysis - Increased sales expenses for brand product marketing have contributed to profit pressure, despite a quick growth in net profit in Q3 2025 due to fair value changes in stocks held by the company [3]. - The company has fully recognized inventory impairment for its brand product, paclitaxel polymer micelles, which has impacted profitability [3]. Revenue and Profit Forecast Adjustments - The revenue forecast for 2025-2026 has been revised down from 10.125 billion yuan and 11.625 billion yuan to 7.449 billion yuan and 7.343 billion yuan, respectively [4]. - The net profit forecast for 2025-2026 has been adjusted from 1.066 billion yuan and 1.294 billion yuan to 612 million yuan and 802 million yuan, respectively [4].

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [5] Core Insights - The company reported a revenue of 613 million yuan for the first three quarters of 2025, representing a year-on-year growth of 32.26%, and a net profit attributable to the parent company of 132 million yuan, up 58.61% year-on-year [1] - The company plans to issue H shares and list on the Hong Kong Stock Exchange to enhance its international strategy and expand its global financing and acquisition channels [3] - The core business focuses on recombinant protein products, which are crucial for the development and production of innovative drugs in cell and gene therapy [4] Financial Performance - For Q3 2025, the company achieved a revenue of 226 million yuan, a year-on-year increase of 37.50%, and a net profit of 48.62 million yuan, up 81.46% year-on-year [1] - The sales expense ratio decreased to 27.54% in Q3 2025, down 2.57 percentage points year-on-year, indicating improved cost management [2] - The company expects revenues for 2025 and 2026 to be adjusted to 845 million yuan and 1.041 billion yuan, respectively, with net profits projected at 208 million yuan and 233 million yuan [5] Strategic Initiatives - The company is enhancing its overseas presence by establishing new subsidiaries and logistics centers to cover global markets comprehensively [3] - It aims to increase R&D investments and strengthen its international team to drive technological innovation [3] - The company has successfully developed nearly 60 high-quality GMP-grade products, which are essential for large-scale production and clinical research in CGT drugs [4]

1. Report Industry Investment Rating No information provided in the content. 2. Core Viewpoints of the Report - The export growth rate turned negative in October, which was lower than expected, mainly due to the high base last year, tightened trade relations, and the misalignment of the Mid - Autumn Festival. However, there is no need to be overly pessimistic about the export situation in the future [1][2][6] - The import growth rate also declined in October, and the trade surplus was lower than market expectations [5] - The export in the fourth quarter may be weaker than that in the third quarter, but external demand has not significantly deteriorated, and there are positive signals in high - frequency data [6][7][8] - The bond market may maintain range - bound fluctuations, and the tariff game entering a "quiet period" may provide a stable external environment for equity assets [8] 3. Summary by Relevant Catalogs 3.1 Export Situation in October - **Overall Export**: In October, the year - on - year export growth rate was - 1.1% in US dollars, the first negative growth since March this year, lower than the market forecast of 2.9% and the previous value of 8.3%. The month - on - month growth rate was - 7.0%, also significantly lower than the average value of the past five years [1] - **By Product Category**: Integrated circuits, automobiles (including chassis), and ships performed well, with year - on - year export growth rates of 26.9%, 34.0%, and 68.4% respectively. Other mechanical and electrical products generally performed poorly. Consumer electronics and labor - intensive product exports weakened. The decline in furniture and home appliance exports may be related to the increase in tariffs [3] - **By Export Destination**: The decline in exports to the US slightly narrowed, with a year - on - year growth rate of - 25.2% and the proportion in total exports rising to 11.4%. Exports to ASEAN and the EU slowed down, with year - on - year growth rates of 11.0% and 0.9% respectively, and the shares remained stable [4] 3.2 Import Situation in October - The year - on - year import growth rate was 1.0% in US dollars, lower than the market forecast of 2.7% and the previous value of 7.4%. The month - on - month growth rate turned negative at - 9.5%, also lower than the average value of the past five years. The trade surplus was 900.7 billion US dollars, lower than the market forecast and the previous value [5] - By major imported commodities, the import growth rate of integrated circuits decreased by 3.8 percentage points to 10.2%, while the import growth rates of iron ore, soybeans, and crude oil increased [5] 3.3 Outlook for the Future - **Export Outlook**: Although the export declined significantly in October, there is no need to be overly pessimistic. The decline was affected by the high base last year and the misalignment of the Mid - Autumn Festival. External demand has not significantly deteriorated and is expected to recover further after the tariff risk decreases. High - frequency data shows positive signals [6][7][8] - **Asset Outlook**: The bond market may maintain range - bound fluctuations, and there is no sign of a trend - based market yet. The tariff game entering a "quiet period" may provide a stable external environment for equity assets [8]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 19.68 CNY [6][17]. Core Insights - The company has launched the "Shufude S500," a smart sleep product that integrates interaction, monitoring, and intervention, addressing key user needs for better sleep [2][3]. - The S500 features a "Digital Sensation Island" system for quick sleep initiation, a mattress designed to enhance deep sleep duration by 12.7 minutes, and a health monitoring system with high accuracy rates for heart and respiratory monitoring [2][3]. - The company is actively collaborating with universities for research in sleep technology and has established a 200 million CNY fund to support innovative projects in the sleep tech sector [4]. Financial Performance - For the first three quarters of 2025, the company reported revenue of 2.2 billion CNY, a year-on-year increase of 0.1%, and a net profit of 150 million CNY, a decrease of 3% [1]. - The adjusted profit forecast for 2025-2027 predicts net profits of 180 million CNY, 230 million CNY, and 280 million CNY, respectively, with corresponding P/E ratios of 39X, 31X, and 25X [5][11]. - The financial data indicates a projected revenue growth rate of 1.85% in 2025, followed by 14.36% in 2026 and 11.78% in 2027 [5][12].

Investment Rating - The investment rating for the company is "Buy" with a maintained rating [6][17]. Core Views - The company has experienced a decline in revenue and net profit in the first three quarters of 2025, with revenue at 1.899 billion yuan, down 8.47% year-on-year, and net profit at 305 million yuan, down 10.63% year-on-year [1][2]. - The decrease in profit is attributed to an increase in VAT from 3% to 13% for products produced by its subsidiary, leading to a decline in revenue [2]. - The company is focusing on multi-level development in the medical beauty sector and accelerating the localization of the ophthalmic industry through self-research and investment integration [2][4]. Financial Performance - In the first three quarters of 2025, the company's gross margin was 70.39%, and the net margin was 15.51%, both remaining relatively stable year-on-year [3]. - The sales expense ratio increased by 2.97 percentage points to 31.62%, while the management expense ratio rose by 1.36 percentage points to 17.04% [3]. - The company’s R&D expense ratio decreased by 1.22 percentage points to 7.85% [3]. Product Development and Market Strategy - The company is actively developing new products, with significant advancements in clinical trials for its enhanced water-light injection products and high-permeability scleral lenses [3]. - The marketing strategy is being adjusted to enhance market share, utilizing a diverse range of hyaluronic acid products with differentiated effects and pricing [4]. - The company aims to optimize its sales structure to compensate for the loss of gross profit due to declining sales prices in the ophthalmic sector [2][4]. Revenue and Profit Forecast - Revenue forecasts for 2025-2027 are adjusted to 2.763 billion yuan, 3.006 billion yuan, and 3.287 billion yuan, respectively, reflecting a downward revision due to insufficient domestic consumption and price competition [4]. - The projected net profit for the same period is 423 million yuan, 473 million yuan, and 526 million yuan, respectively [4].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company reported a revenue of 1.144 billion yuan for the first three quarters of 2025, a year-on-year increase of 6.41%, while the net profit attributable to the parent company was 290 million yuan, a year-on-year decrease of 8.64% [1] - The third quarter saw a revenue of 358 million yuan, a year-on-year decrease of 8.17%, and a net profit of 76.85 million yuan, down 29.85% year-on-year [1] - The company is focusing on strengthening sales channels and has seen a recovery in the orthokeratology lens market, with double-digit growth attributed to significant product performance advantages and ongoing sales channel enhancements [2] Financial Performance - The sales expense ratio for the first three quarters of 2025 was 16.68%, an increase of 2.65 percentage points year-on-year, while the management expense ratio remained stable at 12.08% [3] - Research and development expense ratio decreased to 6.14%, down 1.05 percentage points year-on-year, indicating good control over R&D spending [3] - The company’s sales network covers over 6,000 hospitals and vision centers across 31 provinces, autonomous regions, and municipalities in China, facilitating rapid commercialization of new products [4] Revenue and Profit Forecast - The company’s projected revenues for 2025, 2026, and 2027 are 1.695 billion yuan, 2.085 billion yuan, and 2.552 billion yuan respectively, with net profits of 437 million yuan, 530 million yuan, and 643 million yuan [4] - The revenue growth rates are expected to be 20.18% in 2025, 23.04% in 2026, and 22.41% in 2027 [5] Valuation Metrics - The company’s earnings per share (EPS) for 2025 is projected to be 2.26 yuan, with a price-to-earnings (P/E) ratio of 28.19 [5] - The price-to-book (P/B) ratio is expected to be 4.44 in 2025, while the enterprise value to EBITDA (EV/EBITDA) ratio is projected at 17.67 [5]

Group 1 - The core conclusion of the report is to explore which industries that have underperformed for three consecutive years have a higher probability of reversal in the coming year. It highlights that industries like beauty care, basic chemicals, and social services are currently close to their historical longest periods of underperformance [2][3][10] - The report identifies that defensive industries such as environmental protection, public utilities, and transportation are more likely to exhibit prolonged underperformance due to their weak cyclical nature and low beta characteristics. These industries tend to show a "prolonged decline" feature [2][3][10] - The report indicates that the trend of negative excess returns in public utility sectors is attributed to the small-cap stocks within these sectors, which lack both offensive characteristics during bull markets and stable dividend attributes. The divergence between industry leaders and small-cap stocks has become more pronounced since 2017 [3][24] Group 2 - The report provides statistical analysis from 2007 to 2025, showing that the probability of an industry that has underperformed for three consecutive years winning in the fourth year is inversely related to its historical performance. This suggests that industries with a long history of weak performance are likely to continue this trend [3][10] - The report notes that the current industries that have underperformed for three years and are close to their historical longest underperformance periods include beauty care, basic chemicals, and social services. It also mentions that the food and beverage, agriculture, forestry, animal husbandry, fishery, social services, and pharmaceutical biotechnology sectors have a higher probability of winning in the fourth year [4][38] - The report emphasizes that the monthly trading volume of public utilities, environmental protection, and transportation has been decreasing as a proportion of total A-share trading volume, indicating a long-term downward trend in liquidity for these sectors [4][24][37]

Investment Rating - The investment rating for Anker Innovations is "Buy" with a target price not specified [4] Core Views - The company has shown steady revenue growth, with a reported revenue of 21.02 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 27.8%. The net profit attributable to the parent company reached 1.93 billion yuan, up 31.3% year-on-year [1] - The report highlights that the domestic and overseas revenue growth for the first three quarters of 2025 was 22% and 28% respectively, with the third quarter showing a 19.9% increase in revenue [2] - The report anticipates a recovery in the charging and energy storage business as the impact of previous product recalls diminishes and new products are launched [2] Financial Performance - For Q3 2025, the gross margin was 44.6%, with a net profit margin of 9.8%, reflecting a year-on-year increase of 0.7 percentage points [3] - The company expects net profits for 2025 to reach 2.6 billion yuan, with projected growth rates of 22.93% for 2025, 25.98% for 2026, and 24.20% for 2027 [3][9] - The report provides a detailed financial forecast, indicating a revenue growth rate of 34.32% for 2025 and a projected revenue of 33.19 billion yuan [9][10] Market Position - Anker Innovations maintains a strong market position in the smart innovation sector, with its eufy NVR S4 Max security system ranking first in sales in the UK, second in the US, and third in Germany [2] - The report notes that the charging and energy storage business may face challenges due to previous product recalls and high base effects from last year's natural disasters [2] Future Outlook - The report expresses optimism about the long-term investment value of Anker Innovations, despite short-term disruptions from tariffs and product recalls [3] - The anticipated launch of new products, such as the Anker Prime series and Anker SOLIX C1000 Gen2, is expected to drive growth in the charging and energy storage segment [2]